|
WO2021076554A1
|
|
Antibodies targeting flt3 and use thereof
|
|
WO2021076564A1
|
|
Proteins binding nkg2d, cd16 and flt3
|
|
WO2021041878A1
|
|
Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
|
|
TW202033547A
|
|
Heterodimeric fc-fused proteins
|
|
AR114544A1
|
|
MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16, AND METHODS OF USE
|
|
AU2019319906A1
|
|
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
|
WO2020033664A1
|
|
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
AU2019318425A1
|
|
Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
|
|
AU2019277138A1
|
|
Multi-specific binding proteins and improvements thereon
|
|
KR20210010508A
|
|
Proteins that bind to NKG2D, CD16 and fibroblast active proteins
|
|
EP3790585A1
|
|
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
|
EP3774921A1
|
|
Antibody variable domains targeting dll3, and use thereof
|
|
EP3773676A1
|
|
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
BR112020016939A2
|
|
MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO CD33, NKG2D, AND CD16 AND METHODS OF USE
|
|
KR20200133222A
|
|
Antibody variable domains targeting CD33, and uses thereof
|
|
AU2019218125A1
|
|
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
BR112020016190A2
|
|
ANTIBODY VARIABLE DOMAINS DIRECTING THE NKG2D RECEIVER
|
|
KR20200051789A
|
|
Proteins that bind NKG2D, CD16, and C-type lectin-like molecule-1 (CLL-1)
|
|
AU2018329937A1
|
|
Proteins binding nkg2d, cd16 and nectin4
|
|
AU2018322178A1
|
|
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
